Loading
institutionsInstitution
University Hospital Düsseldorf / CIO Düsseldorf
Düsseldorf's university hospital, a partner in the CIO cancer centre alliance and a leading site for FAPI and PSMA imaging under Frederik Giesel.
Also called: Universitätsklinikum DüsseldorfUKDCentrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf
Overview
University Hospital Düsseldorf forms, with Aachen, Bonn and Cologne, the Centrum für Integrierte Onkologie (CIO ABCD), a German Cancer Aid Oncology Center of Excellence. Its nuclear medicine department is directed by Frederik Giesel, co-inventor of FAPI PET tracers at Heidelberg, and runs theranostic programmes in prostate and neuroendocrine cancers. The hospital has a large paediatric oncology and haematology department, hepatology and liver cancer programmes, and neurosurgical oncology. Trials from the CIO network give patients access to early-phase immunotherapy and cell therapy studies.
Location
Düsseldorf, DE
Type
hospital · Heinrich-Heine-Universität Düsseldorf
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#190 · 30 points (0 Newsweek + 0 NCI + 30 from 15 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Düsseldorf University Hospital, including child institutions. 686 works · 7,181 citations · 73% open access · 9% clinical trials · 2% reviews.
Oncology works per year
1132022
1242023
1682024
1582025
1232026
Most works
- Frederik L. Giesel64 works
- Tanja Fehm46 works
- Iréne Esposito43 works
- Tom Luedde32 works
- Yuriko Mori27 works
- Bastian von Tresckow24 works
- Emil Novruzov24 works
- Sascha Dietrich22 works
- Dirk Schadendorf21 works
- Ralf Gutzmer20 works
Most cited
- FAPI and PSMA PET
- Theranostics
- Paediatric oncology
- CIO ABCD
Kirsten Schmieder
Medical Director and Chair of the Board
NeurosurgeryHospital leadershipNeuro-oncology
Neurosurgeon who serves as Medical Director and Chair of the Board of University Hospital Düsseldorf, home of the CIO Düsseldorf cancer centre.
Sascha Dietrich
Deputy Medical Director
HaematologyLymphomaFunctional precision oncology
Haematologist-oncologist and Deputy Medical Director at University Hospital Düsseldorf, known for drug-response profiling in lymphoma and leukaemia.
Frederik Giesel
Director of Nuclear Medicine, University Hospital Düsseldorf; formerly Heidelberg
Molecular imagingFAPI PETPSMA theranostics
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Similar pages
- PersonUwe Haberkorn
Shares FAP-2286 (177Lu / 68Ga), Heidelberg University Hospital / NCT / DKFZ, FAPI PET, FAP.
- PersonKen Herrmann
Shares FAPI PET, FAP, Lutetium-177 vipivotide tetraxetan, PSMA.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares FAPI PET, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- PersonLouise Emmett
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionEuropean Association of Nuclear Medicine
Shares Frederik Giesel, Heidelberg University Hospital / NCT / DKFZ, FAPI PET, Lutetium-177 vipivotide tetraxetan.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters), Prostate cancer.
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
cancers
fronts
technologies
targets
drugs
Phase 2Theranostic pair (peptide radioligand)
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto